volanesorsen sodium
Nucleic acidexperimental
Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation 2'-O-methoxyethyl (2'-MOE) antisense therapeutic oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C3 (apo-CIII). — Wikipedia
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
4
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02211209)
Timeline
Indications
Mechanism of action
- Apolipoprotein C-III mRNA 3'UTRANTISENSE INHIBITOR
Apolipoprotein C-III mRNA 3'UTR antisense inhibitor
- Apolipoprotein C-IIIINHIBITOR
APOC3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVolanesorsen ↗
- ChEMBLCHEMBL3544994 ↗
- ChEMBLCHEMBL3544989 ↗
Also known as
- free acid
- free acid
- isis 304801
- isis 304801
- isis-304801
- isis-304801
- volanesorsen
- volanesorsen
- volanesorsen
- volanesorsen sodium
- volanesorsen sodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02910635 | Phase 1 | Sep 19, 2016 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
| NCT02658175 | Phase 3 | Dec 31, 2015 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
| NCT02639286 | Phase 2 | Dec 17, 2015 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| NCT02527343 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2015 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
| NCT02300233 | Phase 3 | Dec 1, 2014 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
| NCT02211209 | Phase 3 | Aug 1, 2014 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
| NCT03544060 | N/A | — | Akcea Therapeutics, CaligorRx, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akcea Therapeutics | For profit | 6 | 1 | 3 | 2014 |
| Ionis Pharmaceuticals, Inc. | For profit | 5 | 5 | 2 | 2014 |
| CaligorRx, Inc. | For profit | 1 | 0 | 1 | — |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 2015 |
4 organizations
Page 1 / 1